Therapy Areas: Diabetes
Masters Speciality Pharma unveils Neuropad in Brazil for detection of diabetic foot syndrome
30 October 2019 -

UK pharmaceutical company Masters Speciality Pharma reported on Tuesday the availability of Neuropad in Brazil for the rapid and reliable screening test for diabetic foot syndrome in the country.

Neuropad, which was reportedly launched at the Brazilian Congress of Diabetes held from the 16 – 18 October 2019 in Natal, Brazil, was developed by the German company, TRIGOcare International GmbH.

Diabetic foot syndrome arises from peripheral neuropathy in the foot as a result of diabetes. Peripheral neuropathy may affect up to half of diabetic patients and can lead to foot ulceration and amputation in severe cases. In Brazil over 12.4 million adults have diabetes.

The company added tha5t Neuropad detects the level of moisture in the feet. Reduced moisture from the sweat glands is associated with sub-motor dysfunction, an early sign of peripheral diabetic neuropathy. Neuropad is a unique, patented, adhesive pad impregnated with anhydrous cobalt II chloride that is applied to the sole of each foot and indicates adequate sweat production by means of a blue (dry) to pink (moist) colour change. It is non-invasive, painless and can be administered at-home or in-clinic providing a result in 10-15 minutes.

In addition, the clinical efficacy of this simple screening Neuropad test has been determined in >40 clinical studies involving >3000 diabetic patients and multivariate statistical analysis has shown that diabetic patients with an abnormal Neuropad result were 16 times more likely to develop foot ulceration compared with those having a normal result, concluded the company.

Login
Username:

Password: